Thursday 16 October, 2025
INTRODUCTION A limitation in antitubercular (anti-TB) drug development remains the empiricism based on which companion drugs and their dosing regimens…
Read morePoster: Drug/Disease Modelling - Infection
Model-based extrapolation of the early bacterial activity (EBA) of bedaquiline-combination regimens for the treatment of pulmonary tuberculosis
Thursday 16 October, 2025
INTRODUCTION A limitation in antitubercular drug development remains the empiricism based on which companion drugs and their dose rationale are…
Read moreModelling tissue pharmacokinetics: A comparison of empiric and mechanistic PBPK modelling approaches of different complexity exemplified with moxifloxacin
Thursday 16 October, 2025
Objectives: Suboptimal tissue site exposure is a critical factor for therapeutic failure, potentially stimulating antibiotic resistance and is hence crucial to…
Read moreNetwork-based mathematical modelling of HPV transmission and cervical cancer in Germany.
Thursday 16 October, 2025
Introduction: Worldwide, there are an estimated number of 569,800 cervical cancer cases per year due to an infection with human…
Read moreEvaluation of four distinct weighting schemes in a model averaging and selection approach in model-informed precision dosing of continuously infused vancomycin
Thursday 16 October, 2025
Objectives: Optimal dosing of the antibiotic vancomycin in potentially life-threatening infections can be supported by population pharmacokinetic (PK) models. Although the…
Read moreDrug effect of clofazimine on persisting mycobacteria explain an unexpected increase in bacterial load from patients
Thursday 16 October, 2025
Introduction Clofazimine (CFZ) and pyrazinamide (PZA) are important components of recommended standard multi-drug treatments of TB. Paradoxically, in a Phase…
Read moreIn Silico Clinical Trials for Evaluation of HIV Short-Cycle strategies
Thursday 16 October, 2025
Objectives: The challenge associated with lifelong combination antiretroviral treatments (cART) taken by HIV infected patients have motivated the development of…
Read morePopulation PK and PKPD modeling of TBA-7371 in Healthy Adults and Adults with tuberculosis
Thursday 16 October, 2025
Objectives: Develop a population pharmacokinetics (popPK) model that characterizes the PK of TBA-7371, a drug showing a potent bactericidal anti-Mycobacterium…
Read moreDolutegravir pharmacokinetics in co-administration with rifampicin.
Thursday 16 October, 2025
Objectives: Dolutegravir (DTG) is being introduced as first-line antiretroviral therapy across most of Africa. The antitubercular agent rifampicin (RIF) is…
Read morePopulation pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)
Thursday 16 October, 2025
Objectives: Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are prodrugs of tenofovir, a nucleoside analogue that inhibits human immunodeficiency…
Read more